Evaluation of the Performance of a New OptiScanner™ 5000 System for an Intermittent Glucose Monitoring

Clin Chim Acta. 2015 Jan 1;438:252-4. doi: 10.1016/j.cca.2014.09.008. Epub 2014 Sep 11.

Abstract

Background: Mid-infrared spectral technology has shown a high degree of promise in detecting glucose in plasma. OptiScan Biomedical has developed a glucose monitor based on mid-infrared spectroscopy that withdraws blood samples and measures plasma glucose. The objective of this study was to evaluate the accuracy and performance of the OptiScanner™ 5000 system on different pools of blood.

Methods: This study was performed to validate the blood glucose measurements obtained with the OptiScanner™ 5000 by comparing them to Central Laboratory glucose measurements (VITROS® 5600 Integrated System) as a comparative method across a broad range of glucose values over a three day period to obtain 80-90 paired measurements.

Results: A total of 81 paired measurements, distributed between 33 and 320mg/100mL of glucose, were performed. The aggregate data points were within International Organization for Standardization standards, with 100% of the glucose values within ±15%.

Conclusions: The current study suggests that a mid-IR fixed-wavelength system (OptiScanner) can measure glucose accurately across a wide range of glucose values in plasma of ICU patients.

Keywords: Intermittent glucose monitoring; mid-IR fixed-wavelength system; new OptiScanner™ 5000 system.

Publication types

  • Validation Study

MeSH terms

  • Blood Glucose / analysis*
  • Humans
  • Monitoring, Physiologic / instrumentation
  • Reproducibility of Results
  • Spectrophotometry, Infrared / instrumentation
  • Spectrophotometry, Infrared / methods
  • Spectrophotometry, Infrared / standards*

Substances

  • Blood Glucose